EE200300589A - Ravimkoostised - Google Patents

Ravimkoostised

Info

Publication number
EE200300589A
EE200300589A EEP200300589A EEP200300589A EE200300589A EE 200300589 A EE200300589 A EE 200300589A EE P200300589 A EEP200300589 A EE P200300589A EE P200300589 A EEP200300589 A EE P200300589A EE 200300589 A EE200300589 A EE 200300589A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
EEP200300589A
Other languages
English (en)
Estonian (et)
Inventor
Dixon John
Humphries Robert
Nicol Alexander
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300589A publication Critical patent/EE200300589A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300589A 2001-05-31 2002-05-29 Ravimkoostised EE200300589A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations
PCT/SE2002/001033 WO2002096428A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
EE200300589A true EE200300589A (et) 2004-02-16

Family

ID=20284321

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300589A EE200300589A (et) 2001-05-31 2002-05-29 Ravimkoostised

Country Status (24)

Country Link
US (2) US20040146498A1 (pt)
EP (1) EP1397139A1 (pt)
JP (1) JP2004532869A (pt)
KR (1) KR20040003029A (pt)
CN (1) CN100352442C (pt)
AR (1) AR034343A1 (pt)
AU (1) AU2002305952B2 (pt)
BR (1) BR0210034A (pt)
CA (1) CA2447648A1 (pt)
CO (1) CO5550445A2 (pt)
CZ (1) CZ20033246A3 (pt)
EE (1) EE200300589A (pt)
HU (1) HUP0400069A3 (pt)
IL (1) IL158780A0 (pt)
IS (1) IS7051A (pt)
MX (1) MXPA03010761A (pt)
NO (1) NO20035315D0 (pt)
PL (1) PL366510A1 (pt)
RU (1) RU2331422C2 (pt)
SE (1) SE0101932D0 (pt)
SK (1) SK14732003A3 (pt)
TW (1) TWI232751B (pt)
WO (1) WO2002096428A1 (pt)
ZA (1) ZA200308780B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
JP2007514647A (ja) 2003-10-21 2007-06-07 インスパイアー ファーマシューティカルズ，インコーポレイティド テトラヒドロ−フロ［３，４−ｄ］ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
EP1807086A1 (en) * 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US7566722B2 (en) * 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
RU2012124090A (ru) * 2009-11-09 2013-12-20 Алексион Фармасьютикалз, Инк. Реагенты и способы для определения клеток ii типа при pnh
EP2507242A1 (en) * 2009-12-03 2012-10-10 AstraZeneca AB Co - crystals of a triazolo [4,5 - d]pyrimidine platelet aggregation inhibitor
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
WO2011076749A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CA2836394A1 (en) 2011-06-01 2012-12-06 Astrazeneca Ab Novel ticagrelor co - crystal
CN105377240A (zh) * 2013-05-29 2016-03-02 拉蒂奥法姆有限责任公司 固体药物剂型
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
WO2016116942A1 (en) * 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
WO2016120729A1 (en) * 2015-01-27 2016-08-04 Astrazeneca Ab Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
CN106204544B (zh) * 2016-06-29 2019-04-05 南京中观软件技术有限公司 一种自动提取图像中标志点位置及轮廓的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE69621021T2 (de) * 1995-07-11 2002-10-31 Astrazeneca Ab Inhibitoren der plättchenaggregation
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
EP1161279A1 (en) * 1999-03-11 2001-12-12 Du Pont Pharmaceuticals Company Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations

Also Published As

Publication number Publication date
RU2003133216A (ru) 2005-04-20
IS7051A (is) 2003-11-26
CN1512885A (zh) 2004-07-14
AR034343A1 (es) 2004-02-18
AU2002305952B2 (en) 2007-08-09
US20060189584A1 (en) 2006-08-24
TWI232751B (en) 2005-05-21
HUP0400069A2 (hu) 2004-04-28
CN100352442C (zh) 2007-12-05
EP1397139A1 (en) 2004-03-17
ZA200308780B (en) 2005-02-11
CA2447648A1 (en) 2002-12-05
NO20035315D0 (no) 2003-11-28
US20040146498A1 (en) 2004-07-29
WO2002096428A1 (en) 2002-12-05
BR0210034A (pt) 2004-08-10
CO5550445A2 (es) 2005-08-31
SK14732003A3 (sk) 2004-05-04
HUP0400069A3 (en) 2006-02-28
PL366510A1 (en) 2005-02-07
JP2004532869A (ja) 2004-10-28
KR20040003029A (ko) 2004-01-07
MXPA03010761A (es) 2004-03-02
RU2331422C2 (ru) 2008-08-20
IL158780A0 (en) 2004-05-12
CZ20033246A3 (cs) 2004-02-18
SE0101932D0 (sv) 2001-05-31

Similar Documents

Publication Publication Date Title
FI20011478A (fi) Farmaseuttinen koostumus
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
NO20033556L (no) Farmasöytiske formuleringer
ITMI20010748A0 (it) Composizioni farmaceutiche
NO20033384L (no) Farmasoytisk formulering
EE200300416A (et) Ravimvorm
FI20010780A0 (fi) Parannetut koostumukset
DK1524266T3 (da) Farmaceutisk sammensætning
EE200300589A (et) Ravimkoostised
BR0210619A (pt) composição
NO20035627D0 (no) Farmasöytisk formulering
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
ITTO20020744A0 (it) Composizione
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20044164L (no) Farmasoytiske sammensetninger
EE200300378A (et) Farmatseutiline kompositsioon
ITTO20020745A0 (it) Composizione
EE200200689A (et) Ravimkoostised
FI5468U1 (fi) Farmaseuttinen koostumus
NO20041236L (no) Farmasoytisk formulering
SE0100847D0 (sv) Novel pharmaceutical composition